 VBI Vaccines Inc NASDAQ: VBIV has presented updated 12-month and 18-month overall survival OS data from the Phase 2a study of VBI-1901, the Companys recurrent glioblastoma GBM vaccine VBI-1901 granulocyte-macrophage colony-stimulating factor GM-CSF arm showed 18-month OS of 30 n310 